Reduction of direct and indirect costs in patients with AS receiving etanercept: results from an open-label 36-week extension of the ASCEND study in four European countries.
暂无分享,去创建一个
R. Moots | A. Loft | A. Ostor | S. Qvitzau | D. Kielar | A. Reynolds | M. Ekelund | P. Larsson | P. Järvinen | R. Lindkvist